Immunomedics Files Patent Infringement Lawsuit
Against Cytogen and Bard
Fri Mar 17 12:24:00 EST 2000
MORRIS PLAINS, N.J., Mar 17, 2000 /PRNewswire via COMTEX/ -- Immunomedics,
Inc. (Nasdaq: IMMU) today announced that it has filed a patent infringement suit
against Cytogen Corporation and C.D. Bard, both New Jersey companies. The suit,
filed in the U.S. District Court of New Jersey, alleges that Cytogen's
ProstaScint imaging agent for detection of prostate cancers, which Bard
co-markets, infringes Immunomedics' U.S. Patent No. 4,460,559.
"This patent was one of the first granted to Immunomedics in the field of cancer
detection and therapy," stated Dr. David M. Goldenberg, Immunomedics' Chairman
and CEO. "The Company has been a pioneer in the development of antibody-targeted
agents for diagnosis and treatment of cancer and intends to vigorously enforce
its many patents in this field," added Dr. Goldenberg.
Immunomedics is a biopharmaceutical company focused on the development,
manufacture and commercialization of diagnostic imaging and therapeutic products
for the detection and treatment of cancer and infectious diseases. Integral to
these products are highly specific monoclonal antibodies and antibody fragments
designed to deliver radioisotopes and chemotherapeutic agents to tumors and
sites of infection. The Company's first product, CEA-Scan(R) for the detection
of colorectal cancer, is being marketed in the United States and Europe
(approved in Canada). The Company's second diagnostic imaging product,
LeukoScan(R), is being marketed in Europe for the diagnosis of osteomyelitis
(bone infection). Immunomedics also has several other diagnostic imaging
products and three therapeutic products in clinical trials.
This release, in addition to historical information, contains forward-looking
statements made pursuant to the Private Securities Litigation Reform Act of
1995. Such statements involve significant risks and uncertainties and actual
results could differ materially from those expressed or implied herein. Factors
that could cause such differences include, but are not limited to, risks
associated with new product development (including clinical trials outcome and
regulatory requirements/actions), competitive risks to marketed products and
availability of financing and other sources of capital, as well as the risks
discussed in the Company's Quarterly Report on Form 10-Q for the year ended
December 31, 1999.
Company Contact: Cynthia L. Sullivan, Executive Vice President, 973-605-8200,
extension 109. Visit our web site at immunomedics.com.
SOURCE Immunomedics, Inc.
ragingbull.com |
